Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Simultaneous quantitative LC-MS method of ketamine, midazolam and their metabolites (dehydronorketamine, norketamine and 1hydroxymidazolam) for its application in patients on extracorporeal membrane oxygenation (ECMO) therapy.

Rochani A, Lam E, Tanjuakio J, Hirose H, Kraft WK, Kaushal G.

J Pharm Biomed Anal. 2019 Oct 24:112947. doi: 10.1016/j.jpba.2019.112947. [Epub ahead of print]

PMID:
31708269
2.

No meaningful drug interactions with doravirine, lamivudine and tenofovir disoproxil fumarate coadministration.

Anderson MS, Gilmartin J, Fan L, Yee KL, Kraft WK, Triantafyllou I, Reitmann C, Guo Y, Liu R, Iwamoto M.

Antivir Ther. 2019 Aug 21. doi: 10.3851/IMP3324. [Epub ahead of print]

PMID:
31433304
3.

Drug interactions between direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: considerations for therapy.

Lam E, Bashir B, Chaballa M, Kraft WK.

Expert Rev Clin Pharmacol. 2019 Aug;12(8):781-790. doi: 10.1080/17512433.2019.1637733. Epub 2019 Jul 4. Review.

PMID:
31242782
4.

Pharmacokinetics of vaginal progesterone in pregnancy.

Boelig RC, Zuppa AF, Kraft WK, Caritis S.

Am J Obstet Gynecol. 2019 Sep;221(3):263.e1-263.e7. doi: 10.1016/j.ajog.2019.06.019. Epub 2019 Jun 15.

PMID:
31211965
5.

Could Postnatal Age-Related Uridine Diphosphate Glucuronic Acid Be a Rate-Limiting Factor in the Metabolism of Morphine During the First Week of Life?

Liu T, Lewis TR, Moore JN, Kraft WK, Gauda EB, Sartori D, Moody DE, Gobburu JVS, Ivaturi V.

CPT Pharmacometrics Syst Pharmacol. 2019 Jul;8(7):469-477. doi: 10.1002/psp4.12407. Epub 2019 May 10.

6.

Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome.

Jones HE, Kraft WK.

Clin Perinatol. 2019 Jun;46(2):349-366. doi: 10.1016/j.clp.2019.02.013. Epub 2019 Mar 30. Review.

PMID:
31010564
7.

Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.

Snook AE, Baybutt TR, Xiang B, Abraham TS, Flickinger JC Jr, Hyslop T, Zhan T, Kraft WK, Sato T, Waldman SA.

J Immunother Cancer. 2019 Apr 23;7(1):104. doi: 10.1186/s40425-019-0576-2.

8.

Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil.

McCrea JB, Macha S, Adedoyin A, Marshall W, Menzel K, Cho CR, Liu F, Zhao T, Levine V, Kraft WK, Yoon E, Panebianco D, Stoch SA, Iwamoto M.

J Clin Pharmacol. 2019 Oct;59(10):1331-1339. doi: 10.1002/jcph.1423. Epub 2019 Apr 16.

PMID:
30990905
9.

Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.

Wrishko RE, McCrea JB, Yee KL, Liu W, Panebianco D, Mangin E, Chakravarthy M, Martinez-Cantarin MP, Kraft WK.

Clin Drug Investig. 2019 May;39(5):453-454. doi: 10.1007/s40261-019-00777-6.

PMID:
30895461
10.

Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.

Wrishko RE, McCrea JB, Yee KL, Liu W, Panebianco D, Mangin E, Chakravarthy M, Martinez-Cantarin MP, Kraft WK.

Clin Drug Investig. 2019 May;39(5):441-451. doi: 10.1007/s40261-019-00764-x. Erratum in: Clin Drug Investig. 2019 Mar 20;:.

PMID:
30810914
11.

Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS).

Mangat AK, Schmölzer GM, Kraft WK.

Semin Fetal Neonatal Med. 2019 Apr;24(2):133-141. doi: 10.1016/j.siny.2019.01.009. Epub 2019 Feb 5. Review.

PMID:
30745219
12.

Drug-Drug Interaction Study of Apixaban with Cyclosporine and Tacrolimus in Healthy Volunteers.

Bashir B, Stickle DF, Chervoneva I, Kraft WK.

Clin Transl Sci. 2018 Nov;11(6):590-596. doi: 10.1111/cts.12580. Epub 2018 Jul 27.

13.

The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence Syndrome.

Moore JN, Gastonguay MR, Ng CM, Adeniyi-Jones SC, Moody DE, Fang WB, Ehrlich ME, Kraft WK.

Clin Pharmacol Ther. 2018 Jun;103(6):1029-1037. doi: 10.1002/cpt.1064. Epub 2018 Apr 28.

14.

The Impact of a Transition of Care Program on Acute Myocardial Infarction Readmission Rates.

Marbach JA, Johnson D, Kloo J, Vira A, Keith S, Kraft WK, Margules N, Whellan D.

Am J Med Qual. 2018 Sep/Oct;33(5):481-486. doi: 10.1177/1062860618754702. Epub 2018 Jan 27.

PMID:
29374965
15.

Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling.

Elia J, Ungal G, Kao C, Ambrosini A, De Jesus-Rosario N, Larsen L, Chiavacci R, Wang T, Kurian C, Titchen K, Sykes B, Hwang S, Kumar B, Potts J, Davis J, Malatack J, Slattery E, Moorthy G, Zuppa A, Weller A, Byrne E, Li YR, Kraft WK, Hakonarson H.

Nat Commun. 2018 Jan 16;9(1):4. doi: 10.1038/s41467-017-02244-2.

16.

Subdermal Ultrasound Contrast Agent Injection for Sentinel Lymph Node Identification: An Analysis of Safety and Contrast Agent Dose in Healthy Volunteers.

Machado P, Stanczak M, Liu JB, Moore JN, Eisenbrey JR, Needleman L, Kraft WK, Forsberg F.

J Ultrasound Med. 2018 Jul;37(7):1611-1620. doi: 10.1002/jum.14502. Epub 2017 Dec 5.

17.

Buprenorphine in Neonatal Abstinence Syndrome.

Kraft WK.

Clin Pharmacol Ther. 2018 Jan;103(1):112-119. doi: 10.1002/cpt.930. Epub 2017 Nov 28. Review.

18.

Medication Complications in Extracorporeal Membrane Oxygenation.

Shah AG, Peahota M, Thoma BN, Kraft WK.

Crit Care Clin. 2017 Oct;33(4):897-920. doi: 10.1016/j.ccc.2017.06.010. Review.

PMID:
28887935
19.

Buprenorphine for the Neonatal Abstinence Syndrome.

Kraft WK, Adeniyi-Jones SC, Ehrlich ME.

N Engl J Med. 2017 Sep 7;377(10):997-998. doi: 10.1056/NEJMc1709121. No abstract available.

20.

Tumor necrosis factor inhibitors in psoriatic arthritis.

Mantravadi S, Ogdie A, Kraft WK.

Expert Rev Clin Pharmacol. 2017 Aug;10(8):899-910. doi: 10.1080/17512433.2017.1329009. Epub 2017 May 22. Review.

21.

The Nephrotoxicity of Vancomycin.

Filippone EJ, Kraft WK, Farber JL.

Clin Pharmacol Ther. 2017 Sep;102(3):459-469. doi: 10.1002/cpt.726. Epub 2017 Jun 5. Review.

22.

Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome.

Kraft WK, Adeniyi-Jones SC, Chervoneva I, Greenspan JS, Abatemarco D, Kaltenbach K, Ehrlich ME.

N Engl J Med. 2017 Jun 15;376(24):2341-2348. doi: 10.1056/NEJMoa1614835. Epub 2017 May 4.

23.

Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention.

Weinberg DS, Lin JE, Foster NR, Della'Zanna G, Umar A, Seisler D, Kraft WK, Kastenberg DM, Katz LC, Limburg PJ, Waldman SA.

Cancer Prev Res (Phila). 2017 Jun;10(6):345-354. doi: 10.1158/1940-6207.CAPR-16-0286. Epub 2017 Apr 10.

24.

A Population Pharmacokinetic Model for Vancomycin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Therapy.

Moore JN, Healy JR, Thoma BN, Peahota MM, Ahamadi M, Schmidt L, Cavarocchi NC, Kraft WK.

CPT Pharmacometrics Syst Pharmacol. 2016 Sep;5(9):495-502. doi: 10.1002/psp4.12112. Epub 2016 Sep 17.

25.

Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects.

Kraft WK, Gilmartin JH, Chappell DL, Gheyas F, Walker BM, Nagalla S, Naik UP, Horrow JC, Wrishko RE, Zhang S, Anderson MS.

Clin Transl Sci. 2016 Aug;9(4):221-7. doi: 10.1111/cts.12405. Epub 2016 Jun 15.

26.

Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers.

Nagalla S, Thomson L, Oppong Y, Bachman B, Chervoneva I, Kraft WK.

Clin Transl Sci. 2016 Jun;9(3):176-80. doi: 10.1111/cts.12398. Epub 2016 May 12.

27.

Beta-blocker therapy and impact on outcome after aneurysmal subarachnoid hemorrhage: a cohort study.

Chalouhi N, Daou B, Okabe T, Starke RM, Dalyai R, Bovenzi CD, Anderson EC, Barros G, Reese A, Jabbour P, Tjoumakaris S, Rosenwasser R, Kraft WK, Rincon F.

J Neurosurg. 2016 Sep;125(3):730-6. doi: 10.3171/2015.7.JNS15956. Epub 2016 Jan 22.

PMID:
26799296
28.

Neonatal abstinence syndrome: Pharmacologic strategies for the mother and infant.

Kraft WK, Stover MW, Davis JM.

Semin Perinatol. 2016 Apr;40(3):203-12. doi: 10.1053/j.semperi.2015.12.007. Epub 2016 Jan 12. Review.

29.

A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation.

Gaballa S, Palmisiano N, Alpdogan O, Carabasi M, Filicko-O'Hara J, Kasner M, Kraft WK, Leiby B, Martinez-Outschoorn U, O'Hara W, Pro B, Rudolph S, Sharma M, Wagner JL, Weiss M, Flomenberg N, Grosso D.

Biol Blood Marrow Transplant. 2016 Jan;22(1):141-8. doi: 10.1016/j.bbmt.2015.09.017. Epub 2015 Sep 28.

30.

Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.

Ng CM, Dombrowsky E, Lin H, Erlich ME, Moody DE, Barrett JS, Kraft WK.

Pharmacotherapy. 2015 Jul;35(7):670-80. doi: 10.1002/phar.1610. Epub 2015 Jul 14.

31.

Pharmacologic and clinical evaluation of posaconazole.

Moore JN, Healy JR, Kraft WK.

Expert Rev Clin Pharmacol. 2015 May;8(3):321-34. doi: 10.1586/17512433.2015.1034689. Review.

32.

Current Therapeutic Research is Now Indexed on PubMed.

van den Anker JN, Allegaert K, Kraft WK.

Curr Ther Res Clin Exp. 2014 Nov 9;76:98. doi: 10.1016/j.curtheres.2014.09.005. eCollection 2014 Dec. No abstract available.

33.

Ethanol pharmacokinetics in neonates and infants.

Marek E, Kraft WK.

Curr Ther Res Clin Exp. 2014 Oct 22;76:90-7. doi: 10.1016/j.curtheres.2014.09.002. eCollection 2014 Dec. Review.

34.

Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.

Kraft WK, Chang PS, van Iersel ML, Waskin H, Krishna G, Kersemaekers WM.

Antimicrob Agents Chemother. 2014 Jul;58(7):4020-5. doi: 10.1128/AAC.02448-13. Epub 2014 May 5.

35.

Poor positive predictive value of McConnell's sign on transthoracic echocardiography for the diagnosis of acute pulmonary embolism.

Vaid U, Singer E, Marhefka GD, Kraft WK, Baram M.

Hosp Pract (1995). 2013 Aug;41(3):23-7. doi: 10.3810/hp.2013.08.1065.

PMID:
23948618
36.

Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.

Lawitz E, Sulkowski M, Jacobson I, Kraft WK, Maliakkal B, Al-Ibrahim M, Gordon SC, Kwo P, Rockstroh JK, Panorchan P, Miller M, Caro L, Barnard R, Hwang PM, Gress J, Quirk E, Mobashery N.

Antiviral Res. 2013 Sep;99(3):214-20. doi: 10.1016/j.antiviral.2013.05.015. Epub 2013 Jun 7.

PMID:
23747481
37.

Cardiovascular protection to improve clinical outcomes after subarachnoid hemorrhage: is there a proven role?

Okabe T, Kanzaria M, Rincon F, Kraft WK.

Neurocrit Care. 2013 Apr;18(2):271-84. doi: 10.1007/s12028-012-9804-z. Review.

PMID:
23238984
38.

Limited sampling estimates of epigallocatechin gallate exposures in cirrhotic and noncirrhotic patients with hepatitis C after single oral doses of green tea extract.

Halegoua-De Marzio D, Kraft WK, Daskalakis C, Ying X, Hawke RL, Navarro VJ.

Clin Ther. 2012 Dec;34(12):2279-2285.e1. doi: 10.1016/j.clinthera.2012.10.009. Epub 2012 Nov 13.

PMID:
23153661
39.

MK-0448, a specific Kv1.5 inhibitor: safety, pharmacokinetics, and pharmacodynamic electrophysiology in experimental animal models and humans.

Pavri BB, Greenberg HE, Kraft WK, Lazarus N, Lynch JJ, Salata JJ, Bilodeau MT, Regan CP, Stump G, Fan L, Mehta A, Wagner JA, Gutstein DE, Bloomfield D.

Circ Arrhythm Electrophysiol. 2012 Dec;5(6):1193-201. doi: 10.1161/CIRCEP.111.969782. Epub 2012 Oct 11.

PMID:
23060423
40.

Pharmacologic management of the opioid neonatal abstinence syndrome.

Kraft WK, van den Anker JN.

Pediatr Clin North Am. 2012 Oct;59(5):1147-65. doi: 10.1016/j.pcl.2012.07.006. Epub 2012 Aug 30. Review.

41.

Formulation of buprenorphine for sublingual use in neonates.

Anagnostis EA, Sadaka RE, Sailor LA, Moody DE, Dysart KC, Kraft WK.

J Pediatr Pharmacol Ther. 2011 Oct;16(4):281-4. doi: 10.5863/1551-6776-16.4.281.

42.

Healthy volunteer registries and ethical research principles.

Kupetsky-Rincon EA, Kraft WK.

Clin Pharmacol Ther. 2012 Jun;91(6):965-8. doi: 10.1038/clpt.2012.32.

43.

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease.

Kosoglou T, Kraft WK, Kumar B, Statkevich P, Xuan F, Ma L, Jennings LK, Schiller JE, Langdon RB, Cutler DL.

Eur J Clin Pharmacol. 2012 Jul;68(7):1049-56. doi: 10.1007/s00228-012-1217-6. Epub 2012 Feb 8.

PMID:
22315147
44.

Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.

Pasquinelli C, McPhee F, Eley T, Villegas C, Sandy K, Sheridan P, Persson A, Huang SP, Hernandez D, Sheaffer AK, Scola P, Marbury T, Lawitz E, Goldwater R, Rodriguez-Torres M, Demicco M, Wright D, Charlton M, Kraft WK, Lopez-Talavera JC, Grasela DM.

Antimicrob Agents Chemother. 2012 Apr;56(4):1838-44. doi: 10.1128/AAC.05854-11. Epub 2012 Jan 30.

45.

The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.

Stroh M, Palcza J, McCrea J, Marsilio S, Breidinger S, Panebianco D, Johnson-Levonas A, Kraft WK, Orford K, Murphy G, Agrawal N, Trucksis M, Wagner JA, Iwamoto M.

Cancer Chemother Pharmacol. 2012 May;69(5):1247-53. doi: 10.1007/s00280-011-1819-1.

PMID:
22290273
46.

Model for End-Stage Liver Disease score for predicting outcome in critically ill medical patients with liver cirrhosis.

Cavallazzi R, Awe OO, Vasu TS, Hirani A, Vaid U, Leiby BE, Kraft WK, Kane GC.

J Crit Care. 2012 Aug;27(4):424.e1-6. doi: 10.1016/j.jcrc.2011.11.014. Epub 2012 Jan 9.

PMID:
22227088
47.

Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patients.

Reitman ML, Dishy V, Moreau A, Denney WS, Liu C, Kraft WK, Mejia AV, Matson MA, Stoch SA, Wagner JA, Lai E.

J Clin Pharmacol. 2012 Sep;52(9):1306-16. doi: 10.1177/0091270011419854. Epub 2011 Dec 12.

48.

Prophylaxis for deep vein thrombosis and pulmonary embolism in the surgical patient.

Galanis T, Kraft WK, Merli GJ.

Adv Surg. 2011;45:361-90. Review. No abstract available.

PMID:
21954699
49.

Prevalence of obstructive lung disease in HIV population: a cross sectional study.

Hirani A, Cavallazzi R, Vasu T, Pachinburavan M, Kraft WK, Leiby B, Short W, Desimone J, Squires KE, Weibel S, Kane GC.

Respir Med. 2011 Nov;105(11):1655-61. doi: 10.1016/j.rmed.2011.05.009. Epub 2011 Jun 23.

50.

The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin.

Dallob A, Luo WL, Luk JM, Ratcliffe L, Johnson-Levonas AO, Schwartz JI, Dishy V, Kraft WK, De Hoon JN, Van Hecken A, De Lepeleire I, Radziszewski W, Wagner JA, Lai E.

Platelets. 2011;22(7):495-503. doi: 10.3109/09537104.2011.565433. Epub 2011 Apr 28.

PMID:
21526889

Supplemental Content

Loading ...
Support Center